Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Lowered by StockNews.com
StockNews.com cut shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a buy rating to a hold rating in a ...
Zacks.com on MSN6d
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
Alnylam Pharmaceuticals: Promising Advancements in Alzheimer’s Treatment with RNA Interference Therapeutics
Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to ...
BioSpace7d
Days After BridgeBio Approval, FDA Agrees to Review Alnylam’s Amvuttra in ATTR-CM
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
FierceBiotech14d
Intellia's CRISPR and Alnylam's RNAi data drops present contrasting visions for cardiomyopathy care
But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...
Zacks.com on MSN14d
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
Alnylam Pharmaceuticals ALNY presented new data from its early-stage study of nucresiran (formerly ALN-TTRsc04) for treating ...
Yahoo14d
Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
Alnylam Pharmaceuticals has revealed new interim data from its Phase I trial of nucresiran, a ribonucleic acid interference ...
Alnylam Pharma (ALNY) Gets a Buy from RBC Capital
RBC Capital analyst Luca Issi maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) on November 25 and set a price target of ...
Business Wire15d
Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucresiran ...
BioSpace9d
BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching Competition With Pfizer
BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...
ETF Daily News5d
What is Zacks Research’s Estimate for ALNY FY2024 Earnings?
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Investment analysts at Zacks Research increased their FY2024 ...
Forbes5d
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...